M. Steiger

2.5k total citations
40 papers, 1.8k citations indexed

About

M. Steiger is a scholar working on Neurology, Cellular and Molecular Neuroscience and Epidemiology. According to data from OpenAlex, M. Steiger has authored 40 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Neurology, 7 papers in Cellular and Molecular Neuroscience and 6 papers in Epidemiology. Recurrent topics in M. Steiger's work include Parkinson's Disease Mechanisms and Treatments (22 papers), Neurological disorders and treatments (17 papers) and Botulinum Toxin and Related Neurological Disorders (9 papers). M. Steiger is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (22 papers), Neurological disorders and treatments (17 papers) and Botulinum Toxin and Related Neurological Disorders (9 papers). M. Steiger collaborates with scholars based in United Kingdom, United States and Germany. M. Steiger's co-authors include C. D. Marsden, P. D. Thompson, Brian L. Day, Tim Anderson, Susan H. Fox, Nicholas Fletcher, К. Ray Chaudhuri, Philip D. Thompson, Claudia Trenkwalder and Bryan Kies and has published in prestigious journals such as Neurology, The Journal of Physiology and Annals of Neurology.

In The Last Decade

M. Steiger

39 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Steiger United Kingdom 23 1.2k 302 293 290 285 40 1.8k
Seong‐Beom Koh South Korea 29 1.4k 1.2× 175 0.6× 368 1.3× 374 1.3× 436 1.5× 155 2.6k
Djamel Bensmaïl France 25 1.2k 1.0× 267 0.9× 204 0.7× 131 0.5× 108 0.4× 120 2.1k
Fabrizio Pisano Italy 26 1.2k 1.0× 187 0.6× 137 0.5× 368 1.3× 143 0.5× 58 2.2k
Irene A. Malaty United States 30 2.0k 1.7× 389 1.3× 569 1.9× 346 1.2× 186 0.7× 127 2.7k
Bernard Bussel France 23 548 0.5× 197 0.7× 114 0.4× 253 0.9× 148 0.5× 49 1.5k
Francesco Fattapposta Italy 25 677 0.6× 87 0.3× 294 1.0× 594 2.0× 154 0.5× 126 2.3k
Michael P. Barnes United Kingdom 21 1.4k 1.2× 78 0.3× 243 0.8× 95 0.3× 200 0.7× 63 2.2k
Giuseppe Frazzitta Italy 27 1.5k 1.3× 637 2.1× 228 0.8× 300 1.0× 140 0.5× 71 2.2k
Nora E. Fritz United States 21 407 0.3× 499 1.7× 312 1.1× 99 0.3× 123 0.4× 94 1.8k
Bernardo Lanzillo Italy 22 758 0.6× 68 0.2× 271 0.9× 136 0.5× 407 1.4× 52 1.5k

Countries citing papers authored by M. Steiger

Since Specialization
Citations

This map shows the geographic impact of M. Steiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Steiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Steiger more than expected).

Fields of papers citing papers by M. Steiger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Steiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Steiger. The network helps show where M. Steiger may publish in the future.

Co-authorship network of co-authors of M. Steiger

This figure shows the co-authorship network connecting the top 25 collaborators of M. Steiger. A scholar is included among the top collaborators of M. Steiger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Steiger. M. Steiger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lakshminarayana, Rashmi, Duolao Wang, David J. Burn, et al.. (2017). Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson’s disease. npj Parkinson s Disease. 3(1). 77 indexed citations
2.
3.
4.
Fernandez, Hubert H., David G. Standaert, Robert A. Hauser, et al.. (2014). Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results. Movement Disorders. 30(4). 500–509. 187 indexed citations
5.
Trenkwalder, Claudia, Bryan Kies, Monika Rudzińska, et al.. (2010). Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER). Movement Disorders. 26(1). 90–99. 326 indexed citations
6.
Steiger, M., Wolfgang H. Jost, Francisco Grandas, & Guy Van Camp. (2009). Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review. Journal of Neural Transmission. 116(2). 179–191. 29 indexed citations
7.
Taylor, Joanne, et al.. (2009). Modafinil for Parkinson’s disease fatigue. Journal of Neurology. 257(3). 452–456. 37 indexed citations
8.
Steiger, M.. (2007). Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease. European Journal of Neurology. 15(1). 6–15. 25 indexed citations
9.
Förster, A., et al.. (2007). Thalamic recordings and stimulation in myoclonic dystonia. Clinical Neurophysiology. 118(5). e143–e143. 1 indexed citations
10.
Fox, Susan H., et al.. (2004). A 10 year retrospective audit of long-term apomorphine use in Parkinson?s disease. Journal of Neurology. 251(11). 1370–1374. 81 indexed citations
11.
Varma, T.R.K., Paul Eldridge, Susan H. Fox, et al.. (2003). Variability in Position of the Subthalamic Nucleus Targeted by Magnetic Resonance Imaging and Microelectrode Recordings as Compared to Atlas Co-Ordinates. Stereotactic and Functional Neurosurgery. 80(1-4). 82–87. 28 indexed citations
12.
Fox, Susan H., Monty Silverdale, Mark Kellett, et al.. (2003). Non‐subtype‐selective opioid receptor antagonism in treatment of levodopa‐induced motor complications in Parkinson's disease. Movement Disorders. 19(5). 554–560. 50 indexed citations
13.
Kellett, Mark, et al.. (1998). Hyperekplexia and trismus due to brainstem encephalopathy. Journal of Neurology Neurosurgery & Psychiatry. 65(1). 122–125. 19 indexed citations
14.
Steiger, M., et al.. (1995). Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. Journal of Neurology. 243(1). 68–72. 40 indexed citations
15.
Rose, Sarah, M. Steiger, Mohit Bhatt, et al.. (1994). Plasma HVA Levels Following Debrisoquine Administration Do Not Reflect Cerebral Dopamine Loss in Early Parkinsonʼs Disease. Clinical Neuropharmacology. 17(3). 260–269. 1 indexed citations
16.
Day, Brian L., M. Steiger, P. D. Thompson, & C. D. Marsden. (1993). Effect of vision and stance width on human body motion when standing: implications for afferent control of lateral sway.. The Journal of Physiology. 469(1). 479–499. 343 indexed citations
17.
Steiger, M., Niall Quinn, & C. D. Marsden. (1992). The clinical use of apomorphine in Parkinson's disease. Journal of Neurology. 239(7). 389–393. 25 indexed citations
18.
Steiger, M., Pierre‐Marie Lledo, Niall Quinn, et al.. (1992). Debrisoquine hydroxylation in Parkinson's disease. Acta Neurologica Scandinavica. 86(2). 159–164. 23 indexed citations
19.
Steiger, M., Fabrizio Stocchi, Angelico Carta, et al.. (1991). The Clinical Efficacy of Oral Levodopa Methyl Ester Solution in Reversing Afternoon “Off” Periods in Parkinsonʼs Disease. Clinical Neuropharmacology. 14(3). 241–244. 17 indexed citations
20.
Steiger, M.. (1956). Ein besonderer Fall von Keratitis filiformis. Ophthalmologica. 131(4-5). 315–318. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seong‐Beom Koh Breakdown of academic impact, for papers by Djamel Bensmaïl Breakdown of academic impact, for papers by Fabrizio Pisano Breakdown of academic impact, for papers by Irene A. Malaty Breakdown of academic impact, for papers by Bernard Bussel Breakdown of academic impact, for papers by Francesco Fattapposta Breakdown of academic impact, for papers by Michael P. Barnes Breakdown of academic impact, for papers by Giuseppe Frazzitta Breakdown of academic impact, for papers by Nora E. Fritz Breakdown of academic impact, for papers by Bernardo Lanzillo
Rankless by CCL
2026